Director Robert Postma Acquires 6,274 Shares of Alaunos Therapeutics Common Stock

This Form 4 filing reports that Robert W. Postma, a director of Alaunos Therapeutics, Inc. (TCRT), acquired 6,274 shares of common stock on April 29, 2026, at a price of $2.59 per share. The shares were issued in lieu of board fees. Following this transaction, Postma directly owns 50,146 shares. Additionally, the filing discloses indirect holdings through WaterMill Asset Management Corp. (62,416 shares, where Postma serves as principal) and through his spouse's IRA (24 shares). The total combined holdings amount to 112,586 shares. This transaction represents a significant acquisition by a company director, indicating confidence in the company's future prospects.